Pacific Biosciences
PACB
#7733
Rank
$0.43 B
Marketcap
$1.42
Share price
-4.39%
Change (1 day)
-5.03%
Change (1 year)

P/E ratio for Pacific Biosciences (PACB)

P/E ratio as of July 2026 (TTM): -3.44

According to Pacific Biosciences 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -3.44186. At the end of 2025 the company had a P/E ratio of -1.02.

P/E ratio history for Pacific Biosciences from 2011 to 2026

PE ratio at the end of each year

Year P/E ratio Change
2025-1.02-36.69%
2024-1.61-80.2%
2023-8.1138.76%
2022-5.84-74.58%
2021-23.0-110.63%
2020216-2415.57%
2019-9.34-2.86%
2018-9.61223.99%
2017-2.97
2015-30.5266.11%
2014-8.34102.53%
2013-4.12311.81%
2012-1.00

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Thermo Fisher Scientific
TMO
31.7-1,019.73%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
41.5-1,305.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Illumina
ILMN
37.1-1,177.52%๐Ÿ‡บ๐Ÿ‡ธ USA
PerkinElmer
PKI
15.0-534.84%๐Ÿ‡บ๐Ÿ‡ธ USA
Luminex
LMNX
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
NanoString Technologies
NSTG
-0.0298-99.13%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.